Clinical preclinical Potential buyers include medical device and biotech firms seeking preclinical safety, toxicology, and efficacy studies. Synchrony Labs’ four decades of regulatory‑friendly experience and origin at Duke Medical Center position it as a trusted partner for companies needing robust preclinical data to advance to clinical trials.

Regulatory excellence Highlight the strong compliance track record as a differentiator for customers worried about quality and audit readiness. Position services as enabling smoother regulatory submissions and faster study timelines.

Expansion opportunities Recent activity shows growth in capabilities and visibility since 2018; messaging can target mid‑stage medical device and biotech players looking to scale preclinical programs, potentially offering package deals or phased study plans.

Strategic partnerships Leverage Synchrony Labs’ long‑standing collaborations with major device companies and its academic origins to propose co‑development or exclusive preclinical testing frameworks, appealing to firms seeking trusted customization and tailorable study designs.

Digital maturity Digital footprint and tech stack indicate readiness for inbound marketing and CRM aligned outreach. Emphasize streamlined engagement through LinkedIn Ads, HubSpot, and content that demonstrates return on preclinical investments to convert SOP‑conscious buyers.